{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:48:28Z","timestamp":1790635708160,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1245\/s10434-025-18429-9","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:25:13Z","timestamp":1759494313000},"page":"609-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Carcinoid Syndrome Impacts Long-Term Outcomes After Hepatectomy for Small Bowel Neuroendocrine Tumor Liver Metastasis"],"prefix":"10.1245","volume":"33","author":[{"given":"Markus","family":"Ammann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallbera","family":"Gudmundsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Santol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanja","family":"Podrascanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius A.","family":"Thiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Truty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nagorney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"issue":"8","key":"18429_CR1","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4251\/wjgo.v12.i8.791","volume":"12","author":"M Ahmed","year":"2020","unstructured":"Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol. 2020;12(8):791\u2013807.","journal-title":"World J Gastrointest Oncol."},{"issue":"1","key":"18429_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/01.sla.0000129342.67174.67","volume":"240","author":"MA Maggard","year":"2004","unstructured":"Maggard MA, O\u2019Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117\u201322.","journal-title":"Ann Surg."},{"key":"18429_CR3","doi-asserted-by":"crossref","first-page":"1424839","DOI":"10.3389\/fendo.2024.1424839","volume":"15","author":"B Tan","year":"2024","unstructured":"Tan B, Zhang B, Chen H. Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment. Front Endocrinol (Lausanne). 2024;15:1424839.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"18429_CR4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000481390","volume":"33","author":"G Kloppel","year":"2017","unstructured":"Kloppel G. Neuroendocrine Neoplasms: dichotomy origin and classifications. Visc Med. 2017;33(5):324\u201330.","journal-title":"Visc Med."},{"issue":"4","key":"18429_CR5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334.","journal-title":"Lancet Oncol."},{"issue":"11","key":"18429_CR6","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","volume":"39","author":"L Anthony","year":"2017","unstructured":"Anthony L, Ervin C, Lapuerta P, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of Telotristat Ethyl. Clin Ther. 2017;39(11):2158\u201368.","journal-title":"Clin Ther."},{"issue":"1","key":"18429_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JGO.2015.002980","volume":"3","author":"S Singh","year":"2017","unstructured":"Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017;3(1):43\u201353.","journal-title":"J Glob Oncol."},{"issue":"16","key":"18429_CR8","first-page":"1556","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Ruszniewski P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(16):1556\u20137.","journal-title":"N Engl J Med."},{"issue":"7","key":"18429_CR9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008215730767","volume":"8","author":"ET Janson","year":"1997","unstructured":"Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol. 1997;8(7):685\u201390.","journal-title":"Ann Oncol."},{"issue":"7","key":"18429_CR10","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1530\/ERC-16-0538","volume":"24","author":"WT Zandee","year":"2017","unstructured":"Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. Endocr Relat Cancer. 2017;24(7):R261\u201374.","journal-title":"Endocr Relat Cancer."},{"issue":"3","key":"18429_CR11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.surg.2018.09.008","volume":"165","author":"CW Kimbrough","year":"2019","unstructured":"Kimbrough CW, Beal EW, Dillhoff ME, et al. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. Surgery. 2019;165(3):657\u201363.","journal-title":"Surgery"},{"issue":"2","key":"18429_CR12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","volume":"17","author":"J Rubin","year":"1999","unstructured":"Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600\u20136.","journal-title":"J Clin Oncol."},{"issue":"2","key":"18429_CR13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","volume":"34","author":"MS Khan","year":"2011","unstructured":"Khan MS, El-Khouly F, Davies P, Toumpanakis C, Caplin ME. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34(2):235\u201342.","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"18429_CR14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2009.04083.x","volume":"30","author":"C Toumpanakis","year":"2009","unstructured":"Toumpanakis C, Garland J, Marelli L, et al. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther. 2009;30(7):733\u201340.","journal-title":"Aliment Pharmacol Ther."},{"issue":"28","key":"18429_CR15","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363.","journal-title":"J Clin Oncol."},{"issue":"8","key":"18429_CR16","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1245\/s10434-023-13372-z","volume":"30","author":"H Gudmundsdottir","year":"2023","unstructured":"Gudmundsdottir H, Habermann EB, Vierkant RA, et al. Survival and symptomatic relief after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: long-term follow-up evaluation of more than 500 patients. Ann Surg Oncol. 2023;30(8):4840\u201351.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"18429_CR17","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1245\/ASO.2006.03.071","volume":"13","author":"DA Osborne","year":"2006","unstructured":"Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13(4):572\u201381.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"18429_CR18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172\u201385.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"18429_CR19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.surg.2017.05.030","volume":"163","author":"RE Morgan","year":"2018","unstructured":"Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163(1):218\u201325.","journal-title":"Surgery"},{"issue":"3","key":"18429_CR20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.hpb.2017.08.039","volume":"20","author":"A Ejaz","year":"2018","unstructured":"Ejaz A, Reames BN, Maithel S, et al. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. HPB (Oxford). 2018;20(3):277\u201384.","journal-title":"HPB (Oxford)"},{"issue":"1","key":"18429_CR21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","volume":"165","author":"AT Scott","year":"2019","unstructured":"Scott AT, Breheny PJ, Keck KJ, et al. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165(1):166\u201375.","journal-title":"Surgery"},{"issue":"1","key":"18429_CR22","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","volume":"15","author":"A Frilling","year":"2014","unstructured":"Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8-21.","journal-title":"Lancet Oncol."},{"issue":"7","key":"18429_CR23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839\u201368.","journal-title":"J Natl Compr Canc Netw."},{"issue":"3","key":"18429_CR24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000461583","volume":"105","author":"G Kaltsas","year":"2017","unstructured":"Kaltsas G, Caplin M, Davies P, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. 2017;105(3):245\u201354.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"18429_CR25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00535-014-0934-2","volume":"50","author":"T Ito","year":"2015","unstructured":"Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2015;50(1):58\u201364.","journal-title":"J Gastroenterol."},{"issue":"4","key":"18429_CR26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00000658-200010000-00010","volume":"232","author":"MW Onaitis","year":"2000","unstructured":"Onaitis MW, Kirshbom PM, Hayward TZ, et al. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg. 2000;232(4):549\u201356.","journal-title":"Ann Surg."},{"issue":"6","key":"18429_CR27","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1067\/msy.1998.93105","volume":"124","author":"PM Kirshbom","year":"1998","unstructured":"Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery. 1998;124(6):1063\u201370.","journal-title":"Surgery"},{"key":"18429_CR28","first-page":"662","volume":"10","author":"JM Mota","year":"2016","unstructured":"Mota JM, Sousa LG, Riechelmann RP. Complications from carcinoid syndrome: review of the current evidence. Ecancermedicalscience. 2016;10:662.","journal-title":"Ecancermedicalscience"},{"issue":"3","key":"18429_CR29","first-page":"e7186","volume":"12","author":"AK Gade","year":"2020","unstructured":"Gade AK, Olariu E, Douthit NT. Carcinoid syndrome: a review. Cureus. 2020;12(3):e7186.","journal-title":"Cureus"},{"issue":"7","key":"18429_CR30","doi-asserted-by":"crossref","first-page":"e13146","DOI":"10.1111\/jne.13146","volume":"34","author":"S Grozinsky-Glasberg","year":"2022","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland J, et al. European neuroendocrine tumor society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol. 2022;34(7):e13146.","journal-title":"J Neuroendocrinol."},{"issue":"1","key":"18429_CR31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","volume":"197","author":"JM Sarmiento","year":"2003","unstructured":"Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29\u201337.","journal-title":"J Am Coll Surg."},{"issue":"2","key":"18429_CR32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182\u20138.","journal-title":"Histopathology"},{"issue":"11","key":"18429_CR33","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1007\/s11605-015-2895-z","volume":"19","author":"CR Shubert","year":"2015","unstructured":"Shubert CR, Habermann EB, Bergquist JR, et al. A NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of colorectal resection. J Gastrointest Surg. 2015;19(11):1982\u201394.","journal-title":"J Gastrointest Surg."},{"issue":"2","key":"18429_CR34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg."},{"issue":"5","key":"18429_CR35","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.surg.2010.12.002","volume":"149","author":"M Koch","year":"2011","unstructured":"Koch M, Garden OJ, Padbury R, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International study group of liver surgery. Surgery. 2011;149(5):680\u20138.","journal-title":"Surgery"},{"issue":"5","key":"18429_CR36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.surg.2010.10.001","volume":"149","author":"NN Rahbari","year":"2011","unstructured":"Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the international study group of liver Surgery (ISGLS). Surgery. 2011;149(5):713\u201324.","journal-title":"Surgery"},{"issue":"8","key":"18429_CR37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1477-2574.2011.00319.x","volume":"13","author":"NN Rahbari","year":"2011","unstructured":"Rahbari NN, Garden OJ, Padbury R, et al. Post-hepatectomy haemorrhage: a definition and grading by the international study group of liver surgery (ISGLS). HPB (Oxford). 2011;13(8):528\u201335.","journal-title":"HPB (Oxford)"},{"key":"18429_CR38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jclinane.2018.08.005","volume":"51","author":"MAO Kinney","year":"2018","unstructured":"Kinney MAO, Nagorney DM, Clark DF, et al. Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes. J Clin Anesth. 2018;51:93\u20136.","journal-title":"J Clin Anesth."},{"issue":"15","key":"18429_CR39","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/cncr.25855","volume":"117","author":"H Jann","year":"2011","unstructured":"Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15):3332\u201341.","journal-title":"Cancer"},{"issue":"8","key":"18429_CR40","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.bjc.6603699","volume":"96","author":"V Formica","year":"2007","unstructured":"Formica V, Wotherspoon A, Cunningham D, et al. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007;96(8):1178\u201382.","journal-title":"Br J Cancer"},{"issue":"3","key":"18429_CR41","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.amjcard.2007.08.045","volume":"101","author":"S Bhattacharyya","year":"2008","unstructured":"Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol. 2008;101(3):378\u201381.","journal-title":"Am J Cardiol."},{"key":"18429_CR42","doi-asserted-by":"crossref","first-page":"555963","DOI":"10.3389\/fonc.2020.555963","volume":"10","author":"T Kessoku","year":"2020","unstructured":"Kessoku T, Kobayashi N, Yoneda M, et al. Case reports: transformation of end-stage neuroendocrine tumors with uncontrollable liver metastasis into a novel or additional functional phenotype. Front Oncol. 2020;10:555963.","journal-title":"Front Oncol."},{"issue":"2","key":"18429_CR43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3803\/EnM.2013.28.2.149","volume":"28","author":"JH Ohn","year":"2013","unstructured":"Ohn JH, Kim YG, Lee SH, Jung HS. Transformation of nonfunctioning pancreatic neuroendocrine carcinoma cells into insulin producing cells after treatment with sunitinib. Endocrinol Metab (Seoul). 2013;28(2):149\u201352.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"18429_CR44","first-page":"150032","volume":"2015","author":"A Nahmias","year":"2015","unstructured":"Nahmias A, Grozinsky-Glasberg S, Salmon A, Gross DJ. Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease. Endocrinol Diabetes Metab Case Rep. 2015;2015:150032.","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"issue":"5","key":"18429_CR45","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/MPA.0b013e318212c42d","volume":"40","author":"PG Vashi","year":"2011","unstructured":"Vashi PG, Gupta D, Dahlk S. A unique case of a nonfunctional metastatic pancreatic neuroendocrine tumor transforming into an insulin-secreting tumor with an unusual clinical course. Pancreas. 2011;40(5):781\u20134.","journal-title":"Pancreas"},{"issue":"2","key":"18429_CR46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.surg.2015.03.033","volume":"158","author":"G Spolverato","year":"2015","unstructured":"Spolverato G, Vitale A, Ejaz A, et al. Net health benefit of hepatic resection versus intraarterial therapies for neuroendocrine liver metastases: a Markov decision model. Surgery. 2015;158(2):339\u201348.","journal-title":"Surgery"},{"issue":"3","key":"18429_CR47","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.suronc.2012.05.001","volume":"21","author":"A Saxena","year":"2012","unstructured":"Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21(3):e131\u201341.","journal-title":"Surg Oncol."},{"issue":"6","key":"18429_CR48","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1477-2574.2010.00198.x","volume":"12","author":"ES Glazer","year":"2010","unstructured":"Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford). 2010;12(6):427\u201333.","journal-title":"HPB (Oxford)"},{"issue":"6","key":"18429_CR49","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1245\/s10434-024-15264-2","volume":"31","author":"M Ammann","year":"2024","unstructured":"Ammann M, Kinney MAO, Gudmundsdottir H, et al. Comparison of octreotide and vasopressors as first-line treatment for intraoperative carcinoid crisis. Ann Surg Oncol. 2024;31(6):3976\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"18429_CR50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","volume":"169","author":"FG Que","year":"1995","unstructured":"Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169(1):36\u201342.","journal-title":"Am J Surg."},{"issue":"13","key":"18429_CR51","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1245\/s10434-011-1832-y","volume":"18","author":"SC Mayo","year":"2011","unstructured":"Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18(13):3657\u201365.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"18429_CR52","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","volume":"24","author":"M Fairweather","year":"2017","unstructured":"Fairweather M, Swanson R, Wang J, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24(8):2319\u201325.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18429-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18429-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18429-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:09:59Z","timestamp":1765289399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18429-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18429"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18429-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thorvardur R. Halfdanarson served on the consulting\/advisory board for Ipsen, TerSera, ScioScientifc, Curium, Advanced Accelerator Applications (a Novartis company), Terumo, ITM Isotopen Technologien Muenchen, Perspective Therapeutics, Abdera Therapeutics, Exelixis, Camurus, and Crinetics, and has received research support from Thermo Fisher Scientific, Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, ITM Isotopen Technologien Muenchen, and Perspective Therapeutics. Markus Ammann, Hallbera Gudmundsdottir, Elizabeth B. Habermann, Jonas Santol, Vanja Podrascanin, Yawen Dong, Cornelius A. Thiels, Susanne G. Warner, Mark J. Truty, Michael L. Kendrick, Rory L. Smoot, Heidi M. Connolly, Sean P. Cleary, David M. Nagorney, and Patrick P. Starlinger have no conflicts of interest to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}